Search

Search Constraints

You searched for: Author/Creator Beach, C.L.

Search Results

1. 115 MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q). (April 2015)

2. 116 THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL. (April 2015)

3. 117 A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS). Issue 1 (April 2015)

4. 124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY. (April 2015)

5. 57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE. (April 2015)

6. 96 OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH >30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY. (April 2015)

7. Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes. (April 2017)

8. Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study. (April 2017)

9. Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single‐arm, open‐label phase 2 study. Issue 3 (28th December 2017)

10. Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS). (April 2017)